Non-Small Cell Lung Cancer Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest Drug Approvals by DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, Janssen

DelveInsight's "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Non-Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Small Cell Lung Cancer Market Forecast
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Non-Small Cell Lung Cancer Market Report:
• The Non-Small Cell Lung Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2020, there were 227,875 lung cancer incident cases in the US, of which 85%, or 193,694 people, had non-small cell lung cancer. The highest number of NSCLC cases were found in Germany among the five European nations.
• Additionally, Japan will be responsible for around 117,752 cases in 2020. The United States was expected to have the largest number of NSCLC cases
• The positive clinical findings of patritumab deruxtecan from the extended follow-up phase I study in patients with locally advanced or metastatic TKI-resistant, EGFR-mutated NSCLC were presented by Daiichi Sankyo in June 2021 at the ASCO meeting
• At ASCO 2021, Janssen presented the most recent findings from the CHRYSALIS research, which used lazertinib and amivantamab to treat EGFR mutant (EGFRm) NSCLC that had relapsed after receiving osimertinib but had not yet received chemotherapy
• Key Non-Small Cell Lung Cancer Companies: AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, Janssen, LP, Astrazeneca, Genzyme, Novartis, Seagen Inc., Bristol-Myers Squibb, Celgene, Eisai Inc., and others
• Key Non-Small Cell Lung Cancer Therapies: Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7; Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Amivantamab, AZD2936, ILX651, Capmatinib, SGN-15, Docetaxel, Pemetrexed, Carboplatin, E7389, and others
• The Non-Small Cell Lung Cancer epidemiology based on gender analyzed that Non-Small Cell Lung Cancer
• The Non-Small Cell Lung Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Small Cell Lung Cancer pipeline products will significantly revolutionize the Non-Small Cell Lung Cancer market dynamics.

Non-Small Cell Lung Cancer Overview
About 85% of all cases of lung cancer are NSCLC, making it the most prevalent kind. NSCLC metastasizes to other organs more slowly than SCLC does, and SCLC has significantly fewer cells than SCLC overall.

Get a Free sample for the Non-Small Cell Lung Cancer Market Report
https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Small Cell Lung Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Non-Small Cell Lung Cancer Epidemiology Segmentation:
The Non-Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Non-Small Cell Lung Cancer
• Prevalent Cases of Non-Small Cell Lung Cancer by severity
• Gender-specific Prevalence of Non-Small Cell Lung Cancer
• Diagnosed Cases of Episodic and Chronic Non-Small Cell Lung Cancer

Download the report to understand which factors are driving Non-Small Cell Lung Cancer epidemiology trends @ Non-Small Cell Lung Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers Non-Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non-Small Cell Lung Cancer Therapies and Key Companies
• Telisotuzumab Vedotin: AbbVie
• Ensartinib (X-396): Xcovery
• SAR408701: Sanofi
• Hyleukin-7 (NT-I7; Efineptakin Alfa): NeoImmune Tech
• Avelumab (Bavencio): Merck KGaA and Pfizer
• Sitravatinib: Mirati Therapeutics
• Amivantamab: Janssen, LP
• AZD2936: Astrazeneca
• ILX651: Genzyme
• Capmatinib: Novartis
• SGN-15, Docetaxel: Seagen Inc.
• Pemetrexed: Bristol-Myers Squibb
• Carboplatin: Celgene
• E7389: Eisai Inc.

Discover more about therapies set to grab major Non-Small Cell Lung Cancer market share @ Non-Small Cell Lung Cancer Treatment Market
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Small Cell Lung Cancer Market Strengths
• Premium-price targeted agents with better clinical profile and expansion of therapies in the first-line expected to drive the growth of NSCLC market.
• The development of therapies targeting specific mutations are expected to dominate the upcoming market.

Non-Small Cell Lung Cancer Market Opportunities
• Potential for premium pricing of emerging therapies by showing an edge over current therapies.
• Uptake of potential emerging therapies with better clinical profile, specificity towards mutations occurs in NSCLC and therapies to overcome resistance expected to be fast.

Scope of the Non-Small Cell Lung Cancer Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Non-Small Cell Lung Cancer Companies: AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, Janssen, LP, Astrazeneca, Genzyme, Novartis, Seagen Inc., Bristol-Myers Squibb, Celgene, Eisai Inc., and others
• Key Non-Small Cell Lung Cancer Therapies: Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7; Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Amivantamab, AZD2936, ILX651, Capmatinib, SGN-15, Docetaxel, Pemetrexed, Carboplatin, E7389, and others
• Non-Small Cell Lung Cancer Therapeutic Assessment: Non-Small Cell Lung Cancer current marketed and Non-Small Cell Lung Cancer emerging therapies
• Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer market drivers and Non-Small Cell Lung Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Non-Small Cell Lung Cancer Unmet Needs, KOL's views, Analyst's views, Non-Small Cell Lung Cancer Market Access and Reimbursement

To know more about Non-Small Cell Lung Cancer companies working in the treatment market, visit @ Non-Small Cell Lung Cancer Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Non-Small Cell Lung Cancer Market Report Introduction
2. Executive Summary for Non-Small Cell Lung Cancer
3. SWOT analysis of Non-Small Cell Lung Cancer
4. Non-Small Cell Lung Cancer Patient Share (%) Overview at a Glance
5. Non-Small Cell Lung Cancer Market Overview at a Glance
6. Non-Small Cell Lung Cancer Disease Background and Overview
7. Non-Small Cell Lung Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-Small Cell Lung Cancer
9. Non-Small Cell Lung Cancer Current Treatment and Medical Practices
10. Non-Small Cell Lung Cancer Unmet Needs
11. Non-Small Cell Lung Cancer Emerging Therapies
12. Non-Small Cell Lung Cancer Market Outlook
13. Country-Wise Non-Small Cell Lung Cancer Market Analysis (2019-2032)
14. Non-Small Cell Lung Cancer Market Access and Reimbursement of Therapies
15. Non-Small Cell Lung Cancer Market Drivers
16. Non-Small Cell Lung Cancer Market Barriers
17. Non-Small Cell Lung Cancer Appendix
18. Non-Small Cell Lung Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Non-Small Cell Lung Cancer Pipeline https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Non-Small Cell Lung Cancer Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-Small Cell Lung Cancer market. A detailed picture of the Non-Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Non-Small Cell Lung Cancer treatment guidelines.
Non-Small Cell Lung Cancer Epidemiology https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Small Cell Lung Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Non-Small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.